feedback

Course Director

Manish A. Shah, MD
Manish A. Shah, MD

Center for Advanced Digestive Care
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
New York, New York

Faculty

Nilofer Azad
Nilofer Azad, MD

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Wells A. Messersmith
Wells A. Messersmith, MD, FACP, FASCO

University of Colorado Anschutz Medical Campus
Aurora, Colorado

Accredited by

Medical Learning Institute, Inc.

Activity Description

Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don’t miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape.

Target Audience

The activity is designed to meet the educational needs of oncologists and other clinicians involved in the management of patients with gastrointestinal cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of GI cancers
  • Assess the latest safety and efficacy evidence on immune checkpoint inhibitors for patients with advanced gastrointestinal cancers
  • Examine emerging data regarding the potential of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative, for patients with gastrointestinal cancers
  • Recommend personalized treatment plans incorporating immune checkpoint inhibitors, including possible enrollment in a clinical trial, for eligible patients with advanced gastrointestinal cancers

Providership, Credit, and Support


This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported through educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Chair
Manish A. Shah, MD
Chief, Solid Tumor Oncology Service
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Bartlett Family Associate Professor of Gastrointestinal Oncology
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
New York, New York

Manish A. Shah, MD, has no financial interests/relationships or affiliations in relation to this activity.

Faculty
Nilofer Azad, MD
Director, Developmental Therapeutics Clinical Trials Program
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Nilofer Azad, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bayer; Bristol-Myers Squibb; Genentech; Incyte Corporation; and Merck & Co., Inc.

Wells A. Messersmith, MD, FACP, FASCO
Professor With Tenure, Department of Medicine
Head, Division of Medical Oncology
Associate Director, Translational Research
University of Colorado Anschutz Medical Campus
Aurora, Colorado

Wells A. Messersmith, MD, FACP, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Five Prime Therapeutics and Tanabe Research.
Grant/Research Support from Aduro Biotech; Alexo Therapeutics; AstraZeneca; BeiGene; D3 Pharma; Gossamer Bio; Immunomedics; OncoMed Pharmaceuticals, Inc.; and Pfizer. (Research Support to Institution).

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Natalie I. Vokes, MD
Stacy L. Sims, MSN, RN, CMCN

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC credit. There are no pre-requisites and there is no fee to participate in this activity or to receive MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.